Treatment Studies​

Aribio AR1001

A double-blinded, randomized, placebo-controlled study will be performed to evaluate the efficacy and safety of treating AR1001 (an oral medication) in patients with mild to moderate Alzheimer's disease for 26 weeks.

AZ-Therapies COGNITE Study

AZ Therapies is studying safety and efficacy of a combination therapy medication, to determine whether it can slow the progression of symptoms in early Alzheimer’s disease.  Note: While we are still conducting this study, this study is closed for enrollment.

Memory Improvement Through Nicotine Dosing (MIND) Study 

The purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with MCI. Neuronal nicotinic receptors have long been known to play a critical role in memory function in preclinical studies, with nicotine improving attention, learning, and memory function.  The study will enroll 300 participants for a 2 year period. Participants will be randomized (50:50) to either the transdermal nicotine, beginning at 7mg/day, and increasing to 21mg/day, or placebo skin patch.

Eisai's BAN2401 study for participants with early Alzheimer's Disease (Clarity AD)

​

This study will be conducted to evaluate the efficacy of BAN2401 in participants with early Alzheimer's disease (EAD).

Non-Treatment Studies 

​

Lilly GERAS

The purpose of this study is to learn about health care use, costs, and clinical outcomes over time for amyloid positive participants with early stages of AD in the United States. This study is for research purposes only, and is not intended to treat any medical condition.  Amyloid PET scans are included as part of this study.  Note: While we are still participating in this trial, the study stopped enrolling new subjects as of October 9th 2017.